MX2022002360A - Anticuerpos de anti-il31 para uso veterinario. - Google Patents

Anticuerpos de anti-il31 para uso veterinario.

Info

Publication number
MX2022002360A
MX2022002360A MX2022002360A MX2022002360A MX2022002360A MX 2022002360 A MX2022002360 A MX 2022002360A MX 2022002360 A MX2022002360 A MX 2022002360A MX 2022002360 A MX2022002360 A MX 2022002360A MX 2022002360 A MX2022002360 A MX 2022002360A
Authority
MX
Mexico
Prior art keywords
antibodies
feline
canine
veterinary use
enhanced binding
Prior art date
Application number
MX2022002360A
Other languages
English (en)
Spanish (es)
Inventor
Shyr Jiann Li
Lam Nguyen
Hangjun Zhan
Original Assignee
Kindred Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kindred Biosciences Inc filed Critical Kindred Biosciences Inc
Publication of MX2022002360A publication Critical patent/MX2022002360A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869Interleukin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/54Interleukins [IL]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2022002360A 2019-08-29 2020-08-28 Anticuerpos de anti-il31 para uso veterinario. MX2022002360A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962893799P 2019-08-29 2019-08-29
US201962894526P 2019-08-30 2019-08-30
PCT/US2020/048618 WO2021041972A1 (en) 2019-08-29 2020-08-28 Anti-il31 antibodies for veterinary use

Publications (1)

Publication Number Publication Date
MX2022002360A true MX2022002360A (es) 2022-04-06

Family

ID=74686094

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002360A MX2022002360A (es) 2019-08-29 2020-08-28 Anticuerpos de anti-il31 para uso veterinario.

Country Status (10)

Country Link
US (1) US20220324960A1 (https=)
EP (1) EP4021499A4 (https=)
JP (1) JP7671275B2 (https=)
KR (1) KR20220071191A (https=)
CN (1) CN114555121A (https=)
AU (1) AU2020336210A1 (https=)
BR (1) BR112022002771A2 (https=)
CA (1) CA3147809A1 (https=)
MX (1) MX2022002360A (https=)
WO (1) WO2021041972A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6871948B2 (ja) 2016-04-27 2021-05-19 アッヴィ・インコーポレイテッド 抗il−13抗体を使用する、il−13活性が有害である疾患の治療方法
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
CN114989299B (zh) * 2022-06-21 2023-05-26 北京索莱宝科技有限公司 一种单克隆抗体的组合物及其应用、检测人白细胞介素1β的试剂、试剂盒和方法
CN117186220A (zh) * 2023-07-20 2023-12-08 北京伟杰信生物科技有限公司 可结合白介素31的抗体或其抗原结合片段及其制备方法和应用
CN120865401A (zh) * 2023-11-27 2025-10-31 宁波贝安生物科技有限公司 抗il-31的抗体及其用途
CN121108334A (zh) * 2024-06-11 2025-12-12 优迈生物科技(连云港)有限公司 抗犬il-31的抗体及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820858A (en) * 1993-05-28 1998-10-13 The Scripps Research Institute Methods and compositions for inhibiting CD14 mediated cell activation
US7084257B2 (en) * 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US7261890B2 (en) * 2001-12-21 2007-08-28 Idexx Laboratories, Inc. Methods for using canine immunoglobulin variable domains and caninized antibodies
KR101443050B1 (ko) * 2005-05-06 2014-09-22 지모제넥틱스, 인코포레이티드 Il-31 단클론성 항체 및 사용법
ES2548714T3 (es) * 2006-09-01 2015-10-20 Zymogenetics, Inc. Anticuerpos monoclonales IL-31 y procedimientos de uso
GB2504887B (en) * 2011-05-06 2016-02-03 Nvip Pty Ltd Anti-Nerve growth factor antibodies and methods of preparing and using the same
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
WO2013054127A1 (en) * 2011-10-13 2013-04-18 Nvip Pty Ltd Canine/feline cd20 binding epitope and compositions for binding thereto
CA2886161A1 (en) * 2012-09-29 2014-04-03 The Trustees Of The University Of Pennsylvania Veterinary composition and methods for non-surgical neutering and castration
US9499621B2 (en) * 2013-04-08 2016-11-22 Cytodyn, Inc. Felinized antibodies and methods of treating retroviral infections in felines
CN103965357B (zh) * 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
JP5954916B1 (ja) * 2015-04-14 2016-07-20 中外製薬株式会社 Il−31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物
KR20230119259A (ko) * 2016-04-15 2023-08-16 이뮤넥스트, 인크. 항-인간 vista 항체 및 이의 용도
WO2017192589A1 (en) * 2016-05-02 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to influenza ha and their use and identification
US10093731B2 (en) * 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
MX2020006105A (es) * 2017-12-11 2020-11-09 Ubi Ip Holdings Inmunógenos peptídicos de il-31 y formulaciones de estos para el tratamiento y/o la prevención de la dermatitis atópica.
JP2022500037A (ja) * 2018-09-14 2022-01-04 キンドレッド バイオサイエンシズ インコーポレイテッド 獣医学的使用のための抗il4受容体抗体

Also Published As

Publication number Publication date
KR20220071191A (ko) 2022-05-31
US20220324960A1 (en) 2022-10-13
JP7671275B2 (ja) 2025-05-01
EP4021499A1 (en) 2022-07-06
CN114555121A (zh) 2022-05-27
WO2021041972A1 (en) 2021-03-04
BR112022002771A2 (pt) 2022-08-09
AU2020336210A1 (en) 2022-03-03
CA3147809A1 (en) 2021-03-04
JP2022545259A (ja) 2022-10-26
EP4021499A4 (en) 2024-08-07

Similar Documents

Publication Publication Date Title
MX2022002360A (es) Anticuerpos de anti-il31 para uso veterinario.
MX2024012304A (es) Anticuerpos anti-il31 para uso veterinario
MX2021002971A (es) Anticuerpos del receptor anti-interleucina 4 para uso veterinario.
CY1123791T1 (el) Μονοκλωνικο αντισωμα ιντερλευκινης-31
MX2022013147A (es) Anticuerpos anti-interleucina 31 de acción prolongada para uso veterinario.
MX2022011335A (es) Anticuerpos del receptor anti-interleucina 4 para uso veterinario.
CY1124730T1 (el) Αντισωματα εναντι pd-1 και χρησεις αυτων
EA202091976A1 (ru) Вариабельные домены антител, нацеленные на cd33, и их применение
AU2018254542A1 (en) IL4/IL13 receptor molecule for veterinary use
PE20150023A1 (es) Proteinas de union a antigeno st2
UY37083A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso
ECSP18013690A (es) Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
EA201390146A1 (ru) Антитела к матриксной металлопротеиназе 9
MX2022013149A (es) Moléculas receptoras de interleucina 4/interleucina 13 para uso veterinario.
CL2021003343A1 (es) Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3.
BR112012022342A2 (pt) anticorpos monoclonais dirigidos a cd52
MY167236A (en) Antibodies to matrix metalloproteinase 9
MX391010B (es) Ratones que expresan un repertorio limitado de cadena ligera de inmunoglobulina
ATE476992T1 (de) Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper
EA201600252A1 (ru) Модифицированные антитела к рецепторам антиэпидермального фактора роста и способы их использования
PH12014501931A1 (en) Antibodies to matrix metalloproteinase 9
BR112012022338A2 (pt) anticorpos monoclonais direcionados a cd20
JP2013520990A5 (https=)
MX2021010877A (es) Moleculas de union a cumulo de diferenciacion 3 (cd3).
MX2022001104A (es) Anticuerpos de parvovirus para uso veterinario.